Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

U.S. stock futures rose on Monday after Friday’s sharp fall as investors digested the tariff updates and earnings reports.

This was the stock's second consecutive day of losses.

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

The stock's fall snapped a four-day winning streak.

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...

Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...